The Work We Fund

Funded projects
1,200+
Men's Health Partners
20
Countries
20
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

French Prostate Cancer Award - A Phase III trial of Aspirin and Pravastatin in patients with castrate-resistant prostate cancer (PEACE-4)

Movember Funding to Date

EUR 300,000

What we seek to achieve

There is an urgent medical need to find drugs that are effective and that are affordable and can be combined with the newer treatment modalities without causing too much toxicity. In this clinical trial, Dr Karim Fizazi’s team will investigate the role of statins and aspirin in the treatment of castrate resistant prostate cancer.

Country
France
Co-funded
PHRC, la fondation Cancer du Luxembourg EUR 704,861
Implemented by
Movember Foundation
Project start date
May 2017
Project Status
In Progress

About the project

This project will look at “redesigning” old drugs, aspirin and pravastatin, for new uses in prostate cancer. These drugs have a well-known side effect profile that mostly compares favorably with novel anti-cancer drugs. Moreover the overlapping toxicity is potentially low. 

In addition to the postulated anti-cancer effects both drugs have properties that could counteract the adverse metabolic side effects caused by androgen-deprivation therapy, therefore potentially further reducing morbidity and mortality. 

The role of the statins and the aspirin in castrate resistant prostate cancer will be assessed by a clinical trial. This is a 4 arm, multicenter, international, open phase III randomized trial. 

Such a trial cannot be done in one European country alone in a decent time frame. So it is important to collaborate. This trial is planned to be conducted in France (GETUG), Switzerland (SAKK), Europe (EORTC GU group), Spain (SOGUG), Germany (AUO), and Ireland (ICORG) under the umbrella of the Prostate Cancer Consortium in Europe (PEACE). PEACE is an academic effort to gather forces from different countries to conduct large phase III trials in prostate cancer in Europe.  Two other PEACE phase III trials in Europe have started accruing in 2014. 

This research project underwent a peer review process involving a panel of experts in clinical and translational research across the prostate cancer field.

>
Page 1 of 22